Tata 1mg turns EBITDA positive across core businesses

Tata 1mg achieved EBITDA positivity across all core business verticals in December 2025, with diagnostics crossing ₹600 crore ARR at 40%+ YoY growth and Specialty Pharma up 65% in FY26. For healthcare and digital health stack decisions, this signals that integrated omnichannel models—combining ePharmacy, diagnostics, and AI-driven platforms like its Pulse (used by 75+ pharma companies)—can reach sustainable unit economics at scale in emerging markets.